<DOC>
	<DOCNO>NCT00003747</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine carboplatin temozolomide treat patient unresectable metastatic melanoma .</brief_summary>
	<brief_title>Carboplatin Temozolomide Treating Patients With Unresectable Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose carboplatin temozolomide patient unresectable metastatic melanoma . II . Assess safety cytotoxic combination patient population . III . Assess preliminary evidence efficacy combination patient . OUTLINE : This open label , dose escalation study . Patients receive oral temozolomide daily day 1-5 . Carboplatin IV administer 1 hour day 1 . Courses repeat every 28 day . Treatment continue maximum 6 course absence toxicity disease progression . Sequential dose escalation carboplatin fix dose temozolomide follow sequential dose escalation carboplatin high fix dose temozolomide . Dose escalation cohort 3-6 patient continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxic effect . If combination treatment carboplatin give day 1 temozolomide therapy toxic anticipate , study repeat carboplatin give day 5 temozolomide therapy . Patients follow least every 2 month . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unresectable metastatic melanoma PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : Hemoglobin great 10 g/dL WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.8 mg/dL AST le 3 time upper limit normal ( ULN ) Alkaline phosphatase less 3 time ULN No hepatitis B Renal : Creatinine le 1.4 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : No New York Heart Association class II cardiac disease Pulmonary : No pulmonary disease require oxygen therapy Other : Not pregnant Fertile patient must use effective contraception study 3 month follow No concurrent serious nonmalignant disease No AIDS No uncontrolled infection No uncontrolled diabetes No medical condition interfere take oral temozolomide PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No concurrent biologic therapy Chemotherapy : At least 4 week since prior chemotherapy recover No prior carboplatin temozolomide No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover At least 3 week since prior palliative radiotherapy No concurrent radiotherapy Surgery : No concurrent surgery tumor Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>